ONCAlert | Upfront Therapy for mRCC
Videos  >  

Exploring the Benefits of Ruxolitinib in Second-Line Polycythemia Vera

Srdan Verstovsek, MD, PhD
Published Online:7:00 PM, Wed April 17, 2019


Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the use of ruxolitinib (Jakafi) as a second-line treatment for patients with polycythemia vera (PV).

For the second-line setting in PV, patients typically have a shorter survival, said Verstovsek. At this stage, the disease is more aggressive and a second line of therapy is needed.

Beyond control of the red blood cells, ruxolitinib provides control of the white blood cells, the spleen, and symptoms. In addition, iron is improved and thrombotic events appear to decrease. Verstovsek says this perhaps can have some effect on the overall survival for these patients.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.